Celularity (CELU) Insider Trust Sells 1,204,819 Shares

The Philip Daniele Barach Family Trust recently sold 839,160 shares of CELU on June 19, 2026. This transaction was not part of a planned trading plan, and the exact price of the sale was not disclosed.

Other Institutional Activity in CELU

C V Starr & Co Inc maintained its position in CELU with 764,069 shares worth about $1,016,212. Vanguard Capital Management LLC opened a new position, acquiring 621,105 shares valued at approximately $826,070. Geode Capital Management, LLC increased its stake by 30,886 shares, bringing its total to 191,076 shares worth $254,171, marking a 19.3% increase. BlackRock, Inc. also boosted its holdings by 12,646 shares, ending with 127,501 shares valued at $169,575. Vanguard Fiduciary Trust Co initiated a new position with 79,874 shares valued at $106,232.

Celularity Inc. Stock Down 46.6%

CELU shares traded around $0.76 on Tuesday. The stock has seen a range of interest from various institutional investors, indicating a mixed outlook in the market.

Insider Buying and Selling at Celularity Inc.

On June 19, 2026, the Philip Daniele Barach Family Trust sold 839,160 shares of CELU. This transaction was not under a Rule 10b5-1 trading plan.

Analysts Set New Price Targets

On September 9, 2025, WBB Securities upgraded CELU to a 'buy' rating with a price target of $6. Previously, on May 25, 2023, H.C. Wainwright maintained its 'buy' rating and set a target of $2.5. Morgan Stanley had downgraded the stock to 'sell' with a $1 target on January 30, 2023.

Bottom Line

The recent sale by the Philip Daniele Barach Family Trust adds to the mixed signals from institutional investors and analysts. While some funds are opening new positions or increasing their stakes, others maintain their holdings. Analyst ratings also vary, reflecting differing opinions on CELU's future prospects. As always, insider transactions like these are disclosed after the fact, and investors should consider the broader context.